1. In Vivo
  2. >>Business Strategy

Making His Mark on CMS: McClellan & Cost-Effectiveness

As the new leader of the Centers for Medicare and Medicaid Services (CMS), Mark McClellan, MD, PhD, faces two immediate priorities in implementing the new Medicare Prescription Drug Act. First, he needs to rollout the temporary drug discount card program. Second, he will oversee the promulgation of regulations to further clarify the law's meaning. But this isn't all that's on McClellan's mind. He's thinking more broadly about his opportunity to run CMS.

As the new leader of the Centers for Medicare and Medicaid Services (CMS), Mark McClellan, MD, PhD, faces two immediate priorities in implementing the new Medicare Prescription Drug Act. First, he needs to rollout the temporary drug discount card program by May 3, 2004. Second, he will oversee the promulgation of regulations—proposed rules are expected by October 1, 2004—to further clarify the law's meaning. To accomplish both of these tasks, he'll be appropriating the $1 billion of new CMS funding towards critical efforts like hiring more personnel.

But this isn't all that's on McClellan's mind. While these two mandates will certainly take up a large portion of...

More from Business Strategy

Late-Stage GLP-1 Drug Trials Outside The Cardiometabolic Space

 
• By David Wild

A look at Novo Nordisk, Eli Lilly and other companies' late-stage clinical studies of GLP-1 drugs in indications ranging from neurodegeneration to oncology, and alcoholic liver disease to autoimmune conditions.

Rising Leaders 2025: Metsera’s Whit Bernard’s Musical Path To Biotech Leadership

 
• By David Wild

Metsera CEO Whit Bernard applies an unconventional leadership philosophy to develop next-generation obesity therapeutics, including monthly GLP-1 injections and oral peptides.

AI In Drug Discovery: The Patent Implications

 
• By David Wild

A Q&A with DeAnn Smith, partner and co-chair of the Patent Trial and Appeal Board Proceedings Practice Group at law firm Foley Hoag.

Is Advanced AI Revolutionizing Sales Enablement In Pharma?

 
• By Marina Hickson

Advanced AI is revolutionizing sales enablement by addressing training gaps and performance challenges. Used correctly, it can help to bridge the sales-marketing divide, accelerate ramp-up times and provide managers with data-driven insights.

More from In Vivo

Deals Shaping The Industry, May 2025

 
• By In Vivo Team

An interactive look at pharma, medtech and diagnostics deals made during May 2025. Data courtesy of Biomedtracker.

Podcast: Flagship’s Vision To Predict And Prevent Illness, With Raj Panjabi

 
• By David Wild

Flagship Pioneering senior partner Raj Panjabi discusses shifting health care from reactive treatment to AI-powered prediction and prevention of disease before symptoms emerge.

Rising Leaders 2025: Namrata Saroj On The Importance Of Authenticity In Ophthalmology

 
• By Sushmita Panda

Namrata Saroj, chief business officer of Ocular Therapeutix, is highly respected in the retina community for her contributions to drug development. She talked to In Vivo about her journey in ophthalmology, leadership philosophy and the importance of authenticity in a close-knit specialty.